Glucagon-like peptide-1 (GLP-1) receptor agonists are a family of drugs that are used in the treatment of T2DM, and use of these has shown benefit in treating pathologies of AD and PD in phase II clinical trials [96]. Here, GLP1R is linked to Parkinson disease.